Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation
Sponsor: University of California, San Diego
Summary
The purpose of this study is to examine the effects of combined intranasal esketamine with brief cognitive behavioral therapy for suicide prevention (BCBT-SP) for suicidal ideation (SI) in patients with treatment- resistant depression (TRD). The secondary aim is to identify the biological targets of treatment response using combined transcranial magnetic stimulation and electroencephalography (TMS-EEG). In this project we will recruit patients between the ages of 18 and 70, diagnosed with a major depressive episode with ongoing suicidal ideation present who have failed (or not shown signs of improvement) after at least one prior treatment. The null hypothesis is that there will be no difference in reductions in suicidality at 1-week post-treatment between the combined treatment group and the ketamine only treatment group. The alternative hypothesis is that the combined treatment will result in a greater reduction in suicidal ideation at 1-week post-treatment.
Official title: Combined Intranasal Esketamine and Brief Cognitive Behavioral Therapy for Suicidal Ideation - A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2026-01-09
Completion Date
2029-01
Last Updated
2026-02-09
Healthy Volunteers
No
Conditions
Interventions
Naturalistic Intranasal Esketamine
Naturalistic Intranasal Esketamine is administered in accordance with psychiatrist recommendations
Brief Cognitive Behavioral Therapy for Suicide Prevention
12 session evidence based psychotherapy protocol with weekly 50 minute sessions
Locations (1)
UC San Diego Health - 4S Ranch
San Diego, California, United States